<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>IRESSA- gefitinib tablet, coated </strong><br>AstraZeneca Pharmaceuticals LP<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use IRESSA safely and effectively.  See full prescribing information for IRESSA<br>IRESSA<span class="Sup">®</span>(gefitinib) tablets for oral use<br>Initial U.S. Approval: 2015</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">IRESSA is a tyrosine kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test.  <a href="#ID_531f8966-2d27-4f7a-8f77-27f0c485c48c">(1)</a> </p>
<p class="Highlighta">Limitation of Use: Safety and efficacy of IRESSA have not been established in patients whose tumors have EGFR mutations other than exon 19 deletions or exon 21 (L858R) substitution mutations.  <a href="#ID_531f8966-2d27-4f7a-8f77-27f0c485c48c">(1)</a> </p>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><p class="Highlighta">Recommended dose is 250 mg orally, once daily with or without food.  <a href="#ID_6b501927-e7d3-4de5-a544-b4ee26554267">(2.2)</a> </p></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Tablets:  250 mg.  <a href="#ID_ef52be54-7fc1-486c-ae40-c3e28656c781">(3)</a> </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta">None.  <a href="#ID_be07daf6-e16c-4d92-8859-f931f11ebcbd">(4)</a> </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">Interstitial lung disease</span> (ILD):  ILD occurred in patients taking IRESSA.  Withhold IRESSA for worsening of respiratory symptoms.  Discontinue IRESSA if ILD is confirmed.  (<a href="#ID_4369901b-8d37-4f51-89d5-d64e3281fcd0">2.4</a>, <a href="#ID_2d045521-95aa-4d4d-9692-ed8f004e43df">5.1</a>) </dd>
<dt>•</dt>
<dd>Hepatotoxicity:  Obtain periodic liver function testing.  Withhold IRESSA for Grade 2 or higher for ALT and/or AST elevations.  Discontinue for severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.  (<a href="#ID_4369901b-8d37-4f51-89d5-d64e3281fcd0">2.4</a>, <a href="#ID_2d77f7d3-944b-4aea-9e6d-1a83f173b9b3">5.2</a>)</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4202064" conceptname="Gastrointestinal perforation">Gastrointestinal perforation</span>:  Discontinue IRESSA for <span class="product-label-link" type="condition" conceptid="4202064" conceptname="Gastrointestinal perforation">gastrointestinal perforation</span>.  (<a href="#ID_1131d2b6-1ce8-49f7-a380-78cf3ca3b3b5">2.4</a>, <a href="#ID_a5ee96b2-ff22-43fc-85bc-138eb31489c5">5.3</a>)</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span>:  Withhold IRESSA for Grade 3 or higher <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>.  (<a href="#ID_1131d2b6-1ce8-49f7-a380-78cf3ca3b3b5">2.4</a>, <a href="#ID_c6e16281-54c6-47eb-bbce-fba14bf70e40">5.4</a>)</dd>
<dt>•</dt>
<dd>Ocular Disorders including <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">Keratitis</span>:  Withhold IRESSA for signs and symptoms of severe or worsening ocular disorders including <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">keratitis</span>.  Discontinue for persistent <span class="product-label-link" type="condition" conceptid="373202" conceptname="Corneal ulcer">ulcerative keratitis</span>.  (<a href="#ID_1131d2b6-1ce8-49f7-a380-78cf3ca3b3b5">2.4</a>, <a href="#ID_b08651dd-f6b1-4fdd-993c-c251d00ce1ff">5.5</a>)</dd>
<dt>•</dt>
<dd>Bullous and Exfoliative <span class="product-label-link" type="condition" conceptid="140842" conceptname="Changes in skin texture">Skin Disorders</span>:  Withhold IRESSA for Grade 3 or higher <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> or exfoliative conditions.  (<a href="#ID_1131d2b6-1ce8-49f7-a380-78cf3ca3b3b5">2.4</a>, <a href="#ID_580caeb9-b38c-48a0-a048-92af625dad0b">5.6</a>)</dd>
<dt>•</dt>
<dd>Embryo-fetal Toxicity:  Can cause fetal harm.  Advise of potential risk to a fetus and use of effective contraception.  (<a href="#ID_a349679d-8114-4808-876f-1e8a87878c53">5.7</a>, <a href="#ID_aed3107a-7c80-44f6-8f59-b839375bfd3e">8.1</a>, <a href="#_Ref">8.3</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">The most commonly reported adverse drug reactions (ADRs), reported in more than 20% of the patients and greater than placebo were <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>.  (<a href="#ID_42b19f70-286e-4556-9e7d-5c35885add75">6.1</a>) </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact AstraZeneca at 1-800-236-9933 or FDA at 1-800-FDA-1088 or </span><a href="http://www.fda.gov/medwatch">www.fda.gov/medwatch.</a> </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>CYP3A4 Inducer:  Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer.  (<a href="#ID_1131d2b6-1ce8-49f7-a380-78cf3ca3b3b5">2.4</a>, <a href="#ID_c71f09c1-cb9c-4a55-a671-1aca25ae0ad9">7.1</a>) </dd>
<dt>•</dt>
<dd>CYP3A4 Inhibitor:  Monitor adverse reactions if concomitant use with IRESSA.  (<a href="#ID_c71f09c1-cb9c-4a55-a671-1aca25ae0ad9">7.1</a>)</dd>
<dt>•</dt>
<dd>Drugs Affecting Gastric pH:  Avoid concomitant use of IRESSA with proton pump inhibitors, if possible.  (<a href="#ID_c71f09c1-cb9c-4a55-a671-1aca25ae0ad9">7.1</a>)</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Hemorrhage</span> in patients taking warfarin:  Monitor changes in <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time or INR.  (<a href="#_Ref">7.2</a>)</dd>
</dl></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Lactation:  Discontinue breast-feeding.  <a href="#ID_8168cd39-6a10-42ba-b5ad-57d43110c759">(8.2)</a>
</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.</p>
<p class="HighlightsRevision">Revised: 7/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Patient Selection </a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Recommended Dose</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Administration to Patients Who Have Difficulty Swallowing Solids</a></h2>
<h2><a href="#section-2.4" class="toc">2.4 Dose Modification</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 <span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">Interstitial Lung Disease</span> (ILD)</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Hepatotoxicity</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 <span class="product-label-link" type="condition" conceptid="4202064" conceptname="Gastrointestinal perforation">Gastrointestinal Perforation</span></a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Severe or Persistent <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></a></h2>
<h2><a href="#section-5.5" class="toc">5.5 Ocular Disorders including <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">Keratitis</span> </a></h2>
<h2><a href="#section-5.6" class="toc">5.6 Bullous and Exfoliative <span class="product-label-link" type="condition" conceptid="140842" conceptname="Changes in skin texture">Skin Disorders</span></a></h2>
<h2><a href="#section-5.7" class="toc">5.7 Embryo-fetal Toxicity </a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS </a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience </a></h2>
<h2><a href="#section-6.2" class="toc">6.3 Postmarketing Experience </a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Drugs Affecting Gefitinib Exposure </a></h2>
<h2><a href="#section-7.2" class="toc">7.2 <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Hemorrhage</span> in Patients taking Warfarin </a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.2 Lactation </a></h2>
<h2><a href="#section-8.3" class="toc">8.3 Females and Males of Reproductive Potential </a></h2>
<h2><a href="#section-8.4" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.6" class="toc">8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span> </a></h2>
<h2><a href="#section-8.7" class="toc">8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="ID_531f8966-2d27-4f7a-8f77-27f0c485c48c"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">IRESSA is indicated for the first-line treatment of patients with or metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test [<span class="Italics">see <a href="#ID_fe83de02-e983-4558-94cb-37763a2c98b9">Clinical Studies (14)</a></span>].</p>
<p>Limitation of Use:  Safety and efficacy of IRESSA have not been established in patients with metastatic NSCLC whose tumors have EGFR mutations other than exon 19 deletions or exon 21 (L858R) substitution mutations [<span class="Italics">see <a href="#ID_fe83de02-e983-4558-94cb-37763a2c98b9">Clinical Studies (14)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="ID_baa3f1d8-feb9-4b97-81d8-dfeaa56556b3"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_7b241fd1-1db4-4caa-83bc-92816f31d268"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Patient Selection </h2>
<p class="First">Select patients for the first-line treatment of metastatic NSCLC with IRESSA based on the presence of EGFR exon 19 deletion or exon 21 (L858R) substitution mutations in their tumor [<span class="Italics">see<a href="#ID_531f8966-2d27-4f7a-8f77-27f0c485c48c">Indications and Usage (1)</a></span>, <span class="Italics"><a href="#ID_fe83de02-e983-4558-94cb-37763a2c98b9">Clinical Studies (14)</a></span>].  Information on FDA-approved tests for the detection of EGFR mutations in NSCLC is available at: <a href="http://www.fda.gov/CompanionDiagnostics">http://www.fda.gov/CompanionDiagnostics</a>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_6b501927-e7d3-4de5-a544-b4ee26554267"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Recommended Dose</h2>
<p class="First">The recommended dose of IRESSA is 250 mg orally once daily with or without food until disease progression or unacceptable toxicity.  </p>
<p>Do not take a missed dose within 12 hours of the next dose.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_4369901b-8d37-4f51-89d5-d64e3281fcd0"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Administration to Patients Who Have Difficulty Swallowing Solids</h2>
<p class="First">Immerse IRESSA tablets in 4 to 8 ounces of water by dropping the tablet in water, and stir for approximately 15 minutes.  Immediately drink the liquid or administer through a naso-gastric tube.  Rinse the container with 4 to 8 ounces of water and immediately drink or administer through the naso-gastric tube.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_1131d2b6-1ce8-49f7-a380-78cf3ca3b3b5"></a><a name="section-2.4"></a><p></p>
<h2>2.4 Dose Modification</h2>
<p class="First"><span class="Italics">Dose Modifications for Adverse Drug Reactions</span></p>
<p>Withhold IRESSA (for up to 14 days) for any of the following:</p>
<dl>
<dt>•</dt>
<dd>Acute onset or worsening of pulmonary symptoms (<span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>) [<span class="Italics">see <a href="#ID_2d045521-95aa-4d4d-9692-ed8f004e43df">Warnings and Precautions (5.1)</a></span>]</dd>
<dt>•</dt>
<dd>NCI CTCAE Grade 2 or higher in ALT and/or AST elevations [<span class="Italics">see <a href="#ID_2d77f7d3-944b-4aea-9e6d-1a83f173b9b3">Warnings and Precautions (5.2)</a></span>]</dd>
<dt>•</dt>
<dd>NCI CTCAE Grade 3 or higher <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> [<span class="Italics">see <a href="#ID_c6e16281-54c6-47eb-bbce-fba14bf70e40">Warnings and Precautions (5.4)</a></span>]</dd>
<dt>•</dt>
<dd>Signs and symptoms of severe or worsening ocular disorders including <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">keratitis</span> [<span class="Italics">see <a href="#ID_b08651dd-f6b1-4fdd-993c-c251d00ce1ff">Warnings and Precautions (5.5)</a></span>]</dd>
<dt>•</dt>
<dd>NCI CTCAE Grade 3 or higher <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> [<span class="Italics">see <a href="#ID_580caeb9-b38c-48a0-a048-92af625dad0b">Warnings and Precautions (5.6)</a></span>]</dd>
</dl>
<p>Resume treatment with IRESSA when the adverse reaction fully resolves or improves to NCI CTCAE Grade 1.</p>
<p>Permanently discontinue IRESSA for:</p>
<dl>
<dt>•</dt>
<dd>Confirmed <span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">interstitial lung disease</span> (ILD) [<span class="Italics">see <a href="#ID_2d045521-95aa-4d4d-9692-ed8f004e43df">Warnings and Precautions (5.1)</a></span>]</dd>
<dt>•</dt>
<dd>Severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> [<span class="Italics">see <a href="#ID_2d77f7d3-944b-4aea-9e6d-1a83f173b9b3">Warnings and Precautions (5.2)</a></span>]</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4202064" conceptname="Gastrointestinal perforation">Gastrointestinal perforation</span> [<span class="Italics">see <a href="#ID_a5ee96b2-ff22-43fc-85bc-138eb31489c5">Warnings and Precautions (5.3)</a></span>]</dd>
<dt>•</dt>
<dd>Persistent <span class="product-label-link" type="condition" conceptid="373202" conceptname="Corneal ulcer">ulcerative keratitis</span> [<span class="Italics">see <a href="#ID_b08651dd-f6b1-4fdd-993c-c251d00ce1ff">Warnings and Precautions (5.5)</a></span>]</dd>
</dl>
<p><span class="Italics">Dose Modifications for Drug Interactions</span></p>
<p><span class="Italics">Strong CYP3A4 Inducers</span></p>
<p>Increase IRESSA to 500 mg daily in the absence of severe adverse drug reaction, and resume IRESSA at 250 mg seven days after discontinuation of the strong CYP3A4 inducer [<span class="Italics">see <a href="#ID_880fe9af-b50a-4610-8c04-e22eb76bbdbd">Drug Interactions (7)</a></span>,<span class="Italics"><a href="#ID_736fb4b1-02ee-4c08-95b6-5b2a1bf4f744">Clinical Pharmacology (12.3)</a></span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="ID_ef52be54-7fc1-486c-ae40-c3e28656c781"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">250 mg tablets: round, biconvex, brown film-coated, debossed with "IRESSA 250" on one side and plain on the other side.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="ID_be07daf6-e16c-4d92-8859-f931f11ebcbd"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">None.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="ID_bd2442b2-5405-4b21-8d90-92cf8820ba30"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_2d045521-95aa-4d4d-9692-ed8f004e43df"></a><a name="section-5.1"></a><p></p>
<h2>5.1 <span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">Interstitial Lung Disease</span> (ILD)</h2>
<p class="First">ILD or ILD-like adverse drug reactions (e.g., lung infiltration, <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span>, <span class="product-label-link" type="condition" conceptid="4195694" conceptname="Adult respiratory distress syndrome">acute respiratory distress syndrome</span>, or <span class="product-label-link" type="condition" conceptid="4197819" conceptname="Fibrosis of lung">pulmonary fibrosis</span>) occurred in 1.3% of the 2462 patients who received IRESSA across clinical trials; of these, 0.7% were Grade 3 or higher and 3 cases were fatal.</p>
<p>Withhold IRESSA and promptly investigate for ILD in any patient who presents with worsening of respiratory symptoms such as <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>.  Permanently discontinue IRESSA if ILD is confirmed [<span class="Italics">see <a href="#ID_1131d2b6-1ce8-49f7-a380-78cf3ca3b3b5">Dosage and Administration (2.4)</a>, <a href="#ID_42b19f70-286e-4556-9e7d-5c35885add75">Adverse Reactions (6.1)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_2d77f7d3-944b-4aea-9e6d-1a83f173b9b3"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Hepatotoxicity</h2>
<p class="First">In patients who received IRESSA across clinical trials, 11.4% of patients had increased <span class="product-label-link" type="condition" conceptid="4211515" conceptname="Alanine aminotransferase">alanine aminotransferase</span> (ALT), 7.9% of patients had increased <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">aspartate aminotransferase</span> (AST), and 2.7% of patients had increased bilirubin.  Grade 3 or higher liver test abnormalities occurred in 5.1% (ALT), 3.0% (AST), and 0.7% (bilirubin) of patients.  The incidence of fatal hepatotoxicity was 0.04%.</p>
<p>Obtain periodic liver function testing.  Withhold IRESSA in patients with worsening liver function and discontinue in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> [<span class="Italics">see <a href="#ID_4369901b-8d37-4f51-89d5-d64e3281fcd0">Dosage and Administration (2.4)</a></span>, <span class="Italics"><a href="#_Ref">Adverse Reactions (6.1)</a>, <a href="#ID_cd357a2d-4e47-4d56-8d83-7abd823b1fb4">Use in Specific Populations (8.7)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_a5ee96b2-ff22-43fc-85bc-138eb31489c5"></a><a name="section-5.3"></a><p></p>
<h2>5.3 <span class="product-label-link" type="condition" conceptid="4202064" conceptname="Gastrointestinal perforation">Gastrointestinal Perforation</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4202064" conceptname="Gastrointestinal perforation">Gastrointestinal perforation</span> occurred in three (0.1%) of the 2462 IRESSA-treated patients across clinical trials [<span class="Italics">see <a href="#_Ref">Adverse Reactions (6.1)</a></span>].  Permanently discontinue IRESSA in patients who develop <span class="product-label-link" type="condition" conceptid="4202064" conceptname="Gastrointestinal perforation">gastrointestinal perforation</span> [<span class="Italics">see <a href="#ID_1131d2b6-1ce8-49f7-a380-78cf3ca3b3b5">Dosage and Administration (2.4)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_c6e16281-54c6-47eb-bbce-fba14bf70e40"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Severe or Persistent <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></h2>
<p class="First">Grade 3 or 4 <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> occurred in 3% of 2462 IRESSA-treated patients across clinical trials.  Withhold IRESSA for severe or persistent (up to 14 days) <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> [<span class="Italics">see <a href="#ID_4369901b-8d37-4f51-89d5-d64e3281fcd0">Dosage and Administration (2.4)</a></span>, <span class="Italics"><a href="#_Ref">Adverse Reactions (6.1)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_b08651dd-f6b1-4fdd-993c-c251d00ce1ff"></a><a name="section-5.5"></a><p></p>
<h2>5.5 Ocular Disorders including <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">Keratitis</span> </h2>
<p class="First">Ocular disorders [<span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">keratitis</span> (0.1%), <span class="product-label-link" type="condition" conceptid="4179918" conceptname="Corneal erosion">corneal erosion</span> and aberrant eyelash growth (0.2%), <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, blephritis and <span class="product-label-link" type="condition" conceptid="373204" conceptname="Conjunctival xerosis">dry eye</span> (6.7%)] occurred in the 2462 IRESSA-treated patients across clinical trials.  The incidence of Grade 3 ocular disorders was 0.1% [<span class="Italics">see <a href="#ID_42b19f70-286e-4556-9e7d-5c35885add75">Adverse Reactions (6.1)</a></span>].  Interrupt or discontinue IRESSA for severe, or worsening ocular disorders [<span class="Italics">see <a href="#ID_1131d2b6-1ce8-49f7-a380-78cf3ca3b3b5">Dosage and Administration (2.4)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_580caeb9-b38c-48a0-a048-92af625dad0b"></a><a name="section-5.6"></a><p></p>
<h2>5.6 Bullous and Exfoliative <span class="product-label-link" type="condition" conceptid="140842" conceptname="Changes in skin texture">Skin Disorders</span></h2>
<p class="First">Bullous conditions including <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens Johnson syndrome</span> and <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span> have been reported from treatment with IRESSA.  <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">Erythema multiforme</span> and <span class="product-label-link" type="condition" conceptid="4032934" conceptname="Vesiculobullous rash">dermatitis bullous</span> have been reported in two patients (0.08%) across NSCLC trials (Study 2, Study 3 and Study 4).  IRESSA treatment should be interrupted or discontinued if the patient develops severe bullous, <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blistering</span> or exfoliating conditions.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_a349679d-8114-4808-876f-1e8a87878c53"></a><a name="section-5.7"></a><p></p>
<h2>5.7 Embryo-fetal Toxicity </h2>
<p class="First">Based on its mechanism of action and data from animal reproduction studies IRESSA can cause fetal harm when administered to a pregnant woman.  In animal reproductive studies, oral administration of gefitinib from organogenesis through weaning resulted in fetotoxicity and neonatal <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> at doses below the recommended human dose.  Advise pregnant women of the potential risk to a fetus.  Advise females of reproductive potential to use effective contraception during treatment with IRESSA and for at least two weeks following completion of therapy [<span class="Italics">see Use in Specific Population (<a href="#ID_aed3107a-7c80-44f6-8f59-b839375bfd3e">8.1</a>, <a href="#_Ref">8.3</a>)</span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="ID_880fe9af-b50a-4610-8c04-e22eb76bbdbd"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS </h1>
<p class="First">The following adverse drug reactions are discussed in more detail in other sections of the labeling:</p>
<dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">Interstitial Lung Disease</span> [<span class="Italics">see <a href="#ID_2d045521-95aa-4d4d-9692-ed8f004e43df">Warnings and Precautions (5.1)</a></span>]</dd>
<dt>•</dt>
<dd>Hepatotoxicity [<span class="Italics">see <a href="#ID_2d77f7d3-944b-4aea-9e6d-1a83f173b9b3">Warnings and Precautions (5.2)</a></span>]</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4202064" conceptname="Gastrointestinal perforation">Gastrointestinal Perforation</span> [<span class="Italics">see <a href="#ID_a5ee96b2-ff22-43fc-85bc-138eb31489c5">Warnings and Precautions (5.3)</a></span>]</dd>
<dt>•</dt>
<dd>Severe or Persistent <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> [<span class="Italics">see <a href="#ID_c6e16281-54c6-47eb-bbce-fba14bf70e40">Warnings and Precautions (5.4)</a></span>]</dd>
<dt>•</dt>
<dd>Ocular Disorders including <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">Keratitis</span> [<span class="Italics">see <a href="#ID_b08651dd-f6b1-4fdd-993c-c251d00ce1ff">Warnings and Precautions (5.5)</a></span>]</dd>
<dt>•</dt>
<dd>Bullous and Exfoliative <span class="product-label-link" type="condition" conceptid="140842" conceptname="Changes in skin texture">Skin Disorders</span> [<span class="Italics">see <a href="#ID_580caeb9-b38c-48a0-a048-92af625dad0b">Warning and Precautions (5.6)</a></span>]</dd>
</dl>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_42b19f70-286e-4556-9e7d-5c35885add75"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience </h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<p>The safety of IRESSA is based on the data from 2462 patients with NSCLC who received IRESSA 250 mg daily monotherapy in three randomized clinical studies (Study 2, Study 3 and Study 4).  Patients with a history of <span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">interstitial lung disease</span>, drug-induced interstitial disease, <span class="product-label-link" type="condition" conceptid="4221865" conceptname="Radiation pneumonitis">radiation pneumonitis</span> that required steroid treatment or any evidence of clinically active <span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">interstitial lung disease</span> were excluded from these studies.</p>
<p>Controlled Studies:</p>
<p>Study 2 was a randomized, multicenter, open-label trial in which 1217 patients were randomized to receive first-line treatment for metastatic NSCLC; 607 patients received IRESSA 250 mg daily and 589 patients received carboplatin/paclitaxel.  The median duration of treatment with IRESSA was 5.9 months.  The study population characteristics were:  median age 57 years, age less than 65 years (73%), female (79%), Asian (100%), NSCLC adenocarcinoma histology (100%), never smoker (94%), light ex-smoker (6%), ECOG PS 0 or 1 (90%).</p>
<p>Study 3 was a randomized, multicenter, double-blind, placebo-controlled trial in which 1692 patients were randomized to receive second- or third-line treatment for metastatic NSCLC; of which 1126 patients received IRESSA 250 mg daily and 562 patients received placebo.  The median duration of treatment with IRESSA was 2.9 months.  The study population characteristics were:  median age 62 years, age less than 65 years (60%), female (33%), Caucasian (75%), Asian (21%), NSCLC adenocarcinoma histology (48%), never smoker (22%), ECOG PS 0 or 1 (65%), PS 2 (29%), PS 3 (5%) and two or more prior therapies (51%).</p>
<p>Study 4 was a randomized, multicenter, open-label trial in which 1466 patients were randomized to receive second-line treatment for metastatic NSCLC; 729 patients received IRESSA 250 mg daily and 715 patients received docetaxel.  The median duration of treatment with IRESSA was 2.4 months.  The study population characteristics were:  median age 61 years, age less than 65 years (61%), female (36%), Caucasian (79%), Asian (21%), NSCLC adenocarcinoma histology (54%), never smoker (20%), ECOG PS 0 or 1 (88%) and two or more prior therapies (16%).</p>
<p>The pooled safety database from the three randomized trials was used to evaluate for serious and uncommon adverse drug reactions.  Common adverse reactions were evaluated in Study 3.  The most frequent adverse reactions in Study 3 (incidence of &gt;20% and greater than placebo) reported in IRESSA-treated patients were <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> (47%)and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (29%).  The most frequent fatal adverse reactions in IRESSA-treated patients were <span class="product-label-link" type="condition" conceptid="4256228" conceptname="Respiratory failure">respiratory failure</span> (0.9%), <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> (0.8%), and <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span> (0.5%). </p>
<p>Approximately 5% of IRESSA-treated patients and 2.3% of placebo-treated patients discontinued treatment due to an adverse event.  The most frequent adverse reactions that led to discontinuation in patients treated with IRESSA were <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (0.5%), <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (0.5%) and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (0.4%).</p>
<a name="_RefID0EZHAE"></a><table width="100%">
<caption><span>Table 1 - Selected Adverse Drug Reactions Occurring with an Incidence Rate ≥5% and an Increase of &gt;2% of IRESSA-treated Patients in Study 3</span></caption>
<col width="33%">
<col width="15%">
<col width="19%">
<col width="15%">
<col width="19%">
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Includes <span class="product-label-link" type="condition" conceptid="138463" conceptname="Aphthous ulcer of mouth">Aphthous stomatitis</span>, <span class="product-label-link" type="condition" conceptid="4301764" conceptname="Cheilitis">Cheilitis</span>, <span class="product-label-link" type="condition" conceptid="441334" conceptname="Glossodynia">Glossodynia</span>, <span class="product-label-link" type="condition" conceptid="4094986" conceptname="Ulcer of mouth">Mouth ulceration</span>, <span class="product-label-link" type="condition" conceptid="432661" conceptname="Inflammatory disease of mucous membrane">Mucosal inflammation</span>, Oral mucosal <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blistering</span>, <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">Stomatitis</span>, <span class="product-label-link" type="condition" conceptid="432941" conceptname="Disorder of tongue">Tongue disorder</span>, <span class="product-label-link" type="condition" conceptid="4278836" conceptname="Ulcer on tongue">Tongue ulceration</span></dd>
<dt><a name="footnote-2" href="#footnote-reference-2">†</a></dt>
<dd>Includes <span class="product-label-link" type="condition" conceptid="378425" conceptname="Blepharitis">Blepharitis</span>, <span class="product-label-link" type="condition" conceptid="377283" conceptname="Conjunctival hyperemia">Conjunctival hyperemia</span>, <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">Conjunctivitis</span>, <span class="product-label-link" type="condition" conceptid="373204" conceptname="Conjunctival xerosis">Dry eye</span>, <span class="product-label-link" type="condition" conceptid="4049206" conceptname="Burning sensation in eye">Eye irritation</span>, <span class="product-label-link" type="condition" conceptid="4254270" conceptname="Itching of eye">Eye pruritus</span>, <span class="product-label-link" type="condition" conceptid="381299" conceptname="Swelling of structure of eye">Eye swelling</span>, Eyelid irritation, <span class="product-label-link" type="condition" conceptid="374950" conceptname="Edema of eyelid">Eyelid edema</span>, Eyelids <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span></dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="4" valign="middle"><p class="First"><span class="Bold">Percentage (%) of patients</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Lrule Rrule" align="center" colspan="2"><p class="First"><span class="Bold">IRESSA (N=1126)</span></p></td>
<td class="Botrule Lrule Rrule" align="center" colspan="2"><p class="First"><span class="Bold">Placebo (N=562)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">Adverse Reaction</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">All Grades</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">Grade 3 and 4</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">All Grades</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">Grade 3 and 4</span></p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="5"><p class="First"><span class="Bold">Skin and subcutaneous tissue disorders</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">Skin reactions</span><a href="#_Ref">1</a></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">47%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">2%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">17%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">0.4%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4211923" conceptname="Nail changes">Nail disorders</span><a href="#_Ref">2</a></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">5%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">0.1%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">0.7%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">0%</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="5"><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span></span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span><a href="#_Ref">3</a></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">29%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">3%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">10%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">1%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">14%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">1.2%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">10%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">0.4%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">Stomatitis</span><a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">7%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">0.3%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">4%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">0.2%</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="5"><p class="First"><span class="Bold">Metabolism and nutrition disorders</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Decreased appetite</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">17%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">2.3%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">14%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">2.0%</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="5"><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">Eye disorders</span></span><a name="footnote-reference-2" href="#footnote-2" class="Sup">†</a></p></td></tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">Conjunctivitis</span>/<span class="product-label-link" type="condition" conceptid="378425" conceptname="Blepharitis">blepharitis</span>/dry</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">6%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">0%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">3.2%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">0%</p></td>
</tr>
</tbody>
</table>
<a name="_RefID0ETQAE"></a><table width="100%">
<caption><span>Table 2 - Treatment Emergent Laboratory Abnormalities Occurring More Frequently in IRESSA-Treated Patients in Study 3</span></caption>
<col width="39%">
<col width="14%">
<col width="17%">
<col width="14%">
<col width="17%">
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-3" href="#footnote-reference-3">*</a></dt>
<dd>Patients were allowed to enter the clinical study with lab values of ALT or AST CTCAE grade 1 or 2</dd>
<dt><a name="footnote-4" href="#footnote-reference-4">†</a></dt>
<dd>14% gefitinib patients and 10% placebo patients were CTC grade 1 or 2 ALT at baseline</dd>
<dt><a name="footnote-5" href="#footnote-reference-5">‡</a></dt>
<dd>0.2% of placebo patients were CTC grade 3 at baseline</dd>
<dt><a name="footnote-6" href="#footnote-reference-6">§</a></dt>
<dd>15% gefitinib patients and 12% placebo patients were CTC grade 1 or 2 AST at baseline</dd>
<dt><a name="footnote-7" href="#footnote-reference-7">¶</a></dt>
<dd>0.4% of placebo patients were CTC grade 3 at baseline</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2"><p class="First"><span class="Bold">IRESSA</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2"><p class="First"><span class="Bold">Placebo</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">Adverse Reaction</span></p></td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First"><span class="Bold">All Grades</span></p>
<p><span class="Bold">%</span></p>
</td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First"><span class="Bold">Grade 3 and 4</span></p>
<p><span class="Bold">%</span></p>
</td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First"><span class="Bold">All Grades</span></p>
<p><span class="Bold">%</span></p>
</td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First"><span class="Bold">Grade 3 and 4</span></p>
<p><span class="Bold">%</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4211515" conceptname="Alanine aminotransferase">Alanine aminotransferase</span> increased<a name="footnote-reference-3" href="#footnote-3" class="Sup">*</a></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">38%<a name="footnote-reference-4" href="#footnote-4" class="Sup">†</a></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2.4%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">23%<a href="#footnote-4" class="Sup">†</a></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1.4%<a name="footnote-reference-5" href="#footnote-5" class="Sup">‡</a></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">Aspartate aminotransferase</span> increased<a href="#footnote-3" class="Sup">*</a></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">40%<a name="footnote-reference-6" href="#footnote-6" class="Sup">§</a></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2.0%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">25%<a href="#footnote-6" class="Sup">§</a></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1.3%<a name="footnote-reference-7" href="#footnote-7" class="Sup">¶</a></p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">Proteinuria</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">35%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">4.7%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">31%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">3.3%</p></td>
</tr>
</tbody>
</table>
<p>The following adverse reactions have been reported with IRESSA across NSCLC trials (Study 2, Study 3 and Study 4) and are not listed elsewhere in Section 6:  <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (18%), <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span> (17%), <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span> (9%), <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span> (4.7%), <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> (including <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span> and <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span>) (4.3%), <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span> (2%), <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span> (1.8%), <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> including <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> and <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> (1.1%), elevations in blood creatinine (1.5%), and <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> (0.1%).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_3a8db047-434d-458a-b363-a694bf205794"></a><a name="section-6.2"></a><p></p>
<h2>6.3 Postmarketing Experience </h2>
<p class="First">The following adverse reactions have been identified during post-approval use of IRESSA.  Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
<p><span class="Italics">Renal and urinary disorders</span>:  <span class="product-label-link" type="condition" conceptid="195588" conceptname="Cystitis">cystitis</span>, <span class="product-label-link" type="condition" conceptid="4227291" conceptname="Hemorrhagic cystitis">hemorrhagic cystitis</span></p>
<p><span class="Italics">Skin and subcutaneous tissue disorders</span>:  <span class="product-label-link" type="condition" conceptid="4182711" conceptname="Vasculitis of the skin">cutaneous vasculitis</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="ID_b227be78-1bf8-4067-a4cb-2b2a577754e9"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_c71f09c1-cb9c-4a55-a671-1aca25ae0ad9"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Drugs Affecting Gefitinib Exposure </h2>
<p class="First"><span class="Italics">CYP3A4 Inducer</span></p>
<p>Drugs that are strong inducers of CYP3A4 increase the metabolism of gefitinib and decrease gefitinib plasma concentrations.  Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [<span class="Italics">see <a href="#ID_4369901b-8d37-4f51-89d5-d64e3281fcd0">Dosage and Administration (2.4)</a></span>, <span class="Italics"><a href="#ID_736fb4b1-02ee-4c08-95b6-5b2a1bf4f744">Clinical Pharmacology (12.3)</a></span>].</p>
<p><span class="Italics">CYP3A4 Inhibitor</span></p>
<p>Drugs that are strong inhibitors of CYP3A4 (e.g., ketoconazole and itraconazole) decrease gefitinib metabolism and increase gefitinib plasma concentrations.  Monitor adverse reactions when administering strong CYP3A4 inhibitors with IRESSA.</p>
<p><span class="Italics">Drugs Affecting Gastric pH</span></p>
<p>Drugs that elevate gastric pH (e.g., proton pump inhibitors, histamine H<span class="Sub">2</span>-receptor antagonists, and antacids) may reduce plasma concentrations of gefitinib.  Avoid concomitant use of IRESSA with proton pump inhibitors, if possible.  If treatment with a proton-pump inhibitor is required, take IRESSA 12 hours after the last dose or 12 hours before the next dose of the proton-pump inhibitor.  Take IRESSA 6 hours after or 6 hours before an H<span class="Sub">2</span>-receptor antagonist or an antacid [<span class="Italics">see <a href="#ID_736fb4b1-02ee-4c08-95b6-5b2a1bf4f744">Clinical Pharmacology (12.3)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_0b647029-bc8b-4a29-b832-c86791392122"></a><a name="section-7.2"></a><p></p>
<h2>7.2 <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Hemorrhage</span> in Patients taking Warfarin </h2>
<p class="First">International Normalized Ratio (INR) elevations and/or <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> have been reported in some patients taking warfarin while on IRESSA therapy.  Patients taking warfarin should be monitored regularly for changes in <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time or INR.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="ID_581abec4-0b72-4036-afd3-901ab879fef2"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="ID_aed3107a-7c80-44f6-8f59-b839375bfd3e"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First"><span class="Underline">Risk Summary</span></p>
<p>Based on its mechanism of action and animal data, IRESSA can cause fetal harm when administered to a pregnant woman.  In animal reproductive studies, oral administration of gefitinib from organogenesis through weaning resulted in fetotoxicity and neonatal <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> at doses below the recommended human dose (<span class="Italics">see <a href="#_Ref">Animal Data</a></span>).  Advise pregnant women of the potential hazard to a fetus or potential risk for loss of the pregnancy.</p>
<p>The background risk of major <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> and <span class="product-label-link" type="condition" conceptid="4067106" conceptname="Miscarriage">miscarriage</span> for the indicated population is unknown; however, the background risk in the U.S. general population of major <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> is 2-4% and <span class="product-label-link" type="condition" conceptid="4067106" conceptname="Miscarriage">miscarriage</span> is 15-20% of clinically recognized pregnancies.</p>
<p><span class="Underline">Data</span></p>
<p><span class="Italics">Animal Data</span></p>
<p>A single dose study in rats showed that gefitinib crosses the placenta after an oral dose of 5 mg/kg (30 mg/m<span class="Sup">2</span>, about 0.2 times the recommended human dose on a mg/m<span class="Sup">2</span> basis).  When pregnant rats were treated with 5 mg/kg from the beginning of organogenesis to the end of weaningthere was a reduction in the number of offspring born alive.  This effect was more severe at 20 mg/kg (approximate the human clinical dose on a mg/m<span class="Sup">2</span> basis) and was accompanied by high neonatal mortality soon after parturition.  In rabbits, a dose of 20 mg/kg/day (240 mg/m<span class="Sup">2</span>, about twice the recommended dose in humans on a mg/m<span class="Sup">2</span> basis) caused reduced fetal weight.</p>
</div>
<div class="Section" data-sectionCode="77290-5">
<a name="ID_8168cd39-6a10-42ba-b5ad-57d43110c759"></a><a name="section-8.2"></a><p></p>
<h2>8.2 Lactation </h2>
<p class="First"><span class="Underline">Risk Summary</span></p>
<p>It is not known whether IRESSA is excreted in human milk.  Animal studies indicate the gefitinib and its metabolites are present in rat milk at a concentration higher than those in maternal plasma.  Because of the potential for serious adverse reactions in nursing infants from IRESSA, advise women to discontinue breast-feeding during treatment with IRESSA.</p>
<p><span class="Underline">Data</span></p>
<p><span class="Italics">Animal Data</span></p>
<p>Levels of gefitinib and its metabolites were 11-to-19-fold higher in milk than in blood, after oral exposure of lactating rats to a dose of 5 mg/kg.</p>
</div>
<div class="Section" data-sectionCode="77291-3">
<a name="ID_32a77107-3925-4c54-a304-f0265cf650ff"></a><a name="section-8.3"></a><p></p>
<h2>8.3 Females and Males of Reproductive Potential </h2>
<p class="First"><span class="Underline">Contraception</span></p>
<p>Based on its mechanism of action and animal data, IRESSA can cause fetal harm when administered to a pregnant woman [<span class="Italics">see <a href="#ID_aed3107a-7c80-44f6-8f59-b839375bfd3e">Use in Specific Populations (8.1)</a></span>].  Advise females of reproductive potential to use effective contraception during treatment with IRESSA and for at least two weeks following completion of therapy.</p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">Infertility</span></span></p>
<p>IRESSA may result in reduced fertility in females of reproductive potential [<span class="Italics">see <a href="#ID_1b6766df-089a-4bee-8830-896d43ad8137">Nonclinical Toxicology (13.1)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="ID_e67633f1-0439-496c-8798-6a9077ded3d7"></a><a name="section-8.4"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">The safety and effectiveness of IRESSA in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="ID_cd357a2d-4e47-4d56-8d83-7abd823b1fb4"></a><a name="section-8.5"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Of the 823 patients enrolled in two randomized, active-controlled clinical trials 374 patients (45%) were 65 years and older, and 93 patients (11%) were 75 years and older.  No overall differences in safety were observed between patients 65 years and older and those younger than 65 years.  There is insufficient information to assess for differences in efficacy between older and younger patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_55f24a4a-aafe-469f-ac6f-e4ddc32b371c"></a><a name="section-8.6"></a><p></p>
<h2>8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span> </h2>
<p class="First">Less than four percent (&lt;4%) of gefitinib and its metabolites are excreted via the kidney.  No clinical studies were conducted with IRESSA in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_ce6adf8e-1aea-4074-8a22-c98b474f8495"></a><a name="section-8.7"></a><p></p>
<h2>8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">The systemic exposure of gefitinib was compared in patients with mild, moderate, or severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> due to cirrhosis (according to Child-Pugh classification) and healthy subjects with normal hepatic function (N=10/group).  The mean systemic exposure (AUC<span class="Sub">0-∞</span>) was increased by 40% in patients with mild impairment, 263% in patients with moderate impairment, and 166% in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.  Monitor adverse reactions when IRESSA is administered to patients with moderate and severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.</p>
<p>In a study comparing 13 patients with liver <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">metastases</span> and moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (addition of CTC grade of baseline AST/<span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span>, ALP, and bilirubin equals 3 to 5) to 14 patients with liver <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">metastases</span> and normal hepatic function, the systemic exposure of gefitinib was similar [<span class="Italics">see <a href="#ID_2d77f7d3-944b-4aea-9e6d-1a83f173b9b3">Warnings and Precautions (5.2)</a></span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="ID_2bd2165b-af0e-4bfb-85b5-0295dd6b7e72"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">Twenty three patients were treated weekly with doses from 1500 mgto3500 mg, and IRESSA exposure did not increase with increasing dose.  Adverse events were mostly mild to moderate in severity, and were consistent with the known safety profile of IRESSA.  In the event of suspected <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, interrupt IRESSA, institute supportive care, and observe until clinical stabilization.  There are no specific measures/treatments that should be taken following IRESSA overdosing.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="ID_ee71e339-b20f-48b6-979b-d4c0671f57aa"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Gefitinib is a kinase inhibitor.</p>
<p>The chemical name of gefitinib is 4-Quinazolinamine <span class="Italics">N</span>-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholinyl) propoxy] and the following structural formula:</p>
<div class="Figure">
<a name="id-1734167980"></a><img alt="structural formula for gefitinib" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=827d60e8-7e07-41b7-c28b-49ef1c4a5a41&amp;name=image-01.jpg">
</div>
<p>Gefitinib has the molecular formula C<span class="Sub">22</span>H<span class="Sub">24</span>ClFN<span class="Sub">4</span>O<span class="Sub">3</span>, a relative molecular <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> of 446.9 daltons and is a white-colored powder.  Gefitinib is a free base.  The molecule has pK<span class="Sub">a</span>s of 5.4 and 7.2.  Gefitinib can be defined as sparingly soluble at pH 1, but is practically insoluble above pH 7, with the solubility decreasing sharply between pH 4 and pH 6.  In non-aqueous solvents, gefitinib is freely soluble in glacial acetic acid and dimethyl sulfoxide, soluble in pyridine, sparingly soluble in tetrahydrofuran, and slightly soluble in methanol, ethanol (99.5%), ethyl acetate, propan-2-ol and acetonitrile.</p>
<p>IRESSA<span class="Sup">®</span> (gefitinib) tablets are available as brown film-coated tablets, containing 250 mg of gefitinib, for oral administration.  The inactive ingredients of the tablet core of IRESSA tablets are lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, povidone, sodium lauryl sulfate and magnesium stearate.  The tablet coating is composed of hypromellose, polyethylene glycol 300, titanium dioxide, red ferric oxide and yellow ferric oxide.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="ID_344a8479-fc42-4ddb-a767-2ae84eae8b70"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="ID_9b9a69eb-5b30-490f-9a7c-4ab773b16c59"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">The epidermal growth factor receptor (EGFR) is expressed on the cell surface of both normal and cancer cells and plays a role in the processes of cell growth and proliferation.  Some EGFR activating mutations (exon 19 deletion or exon 21 point mutation L858R) within NSCLC cells have been identified as contributing to the promotion of tumor cell growth, blocking of <span class="product-label-link" type="condition" conceptid="4048757" conceptname="Apoptosis">apoptosis</span>, increasing the production of angiogenic factors and facilitating the processes of <span class="product-label-link" type="condition" conceptid="4147162" conceptname="Secondary malignant neoplasm of respiratory and digestive systems">metastasis</span>.</p>
<p>Gefitinib reversibly inhibits the kinase activity of wild-type and certain activating mutations of EGFR, preventing autophosphorylation of tyrosine residues associated with the receptor, thereby inhibiting further downstream signalling and blocking EGFR-dependent proliferation.</p>
<p>Gefitinib binding affinity for EGFR exon 19 deletion or exon 21 point mutation L858R mutations is higher than its affinity for the wild-type EGFR.  Gefitinib also inhibits IGF and PDGF-mediated signalling at clinically relevant concentrations; inhibition of other tyrosine kinase receptors has not been fully characterized. </p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="ID_736fb4b1-02ee-4c08-95b6-5b2a1bf4f744"></a><a name="section-11.2"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First"><span class="Italics">Absorption and Distribution</span></p>
<p>The mean oral bioavailability of gefitinib is 60%, with peak plasma levels occurring 3-7 hours after dosing.  Food does not alter gefitinib bioavailability to a clinically meaningful extent.  IRESSA can be administered with or without food.  Gefitinib is extensively distributed throughout the body with a mean steady state volume of distribution of 1400 L following intravenous administration.  <span class="Italics">In vitro</span> binding of gefitinib to human plasma proteins (serum albumin and αl-acid glycoprotein) is 90%, independent of drug concentrations.  Gefitinib is a substrate for the membrane transport P-glycoprotein (P-gp), but it is unlikely to influence gefitinib absorption as P-gp is saturated at higher concentrations.</p>
<p><span class="Italics">Metabolism and Elimination</span></p>
<p>Gefitinib undergoes extensive hepatic metabolism in humans, predominantly by CYP3A4.  Three sites of biotransformation have been identified:  metabolism of the N-propoxymorpholino-group, demethylation of the methoxy-substituent on the quinazoline, and oxidative defluorination of the halogenated phenyl group.  Five metabolites have been fully identified in fecal extracts and the major active component was O-desmethyl gefitinib produced by CYP2D6 metabolism and accounted for 14% of the dose.</p>
<p>Eight metabolites were identified in human plasma.  Only O-desmethyl gefitinib has exposure comparable to gefitinib.  Although this metabolite has similar EGFR-TK activity to gefitinib in the isolated enzyme assay, it had only 1/14 of the potency of gefitinib in one of the cell-based assays.</p>
<p>Gefitinib is cleared primarily by the liver, with total plasma clearance and elimination half-life of 48 hours after intravenous administration.  The inter-subject variability (coefficient of variation) for AUC in healthy subjects was 67%.  Daily oral administration of gefitinib to cancer patients resulted in a two-fold accumulation compared to single dose administration.  Steady state plasma concentrations are achieved within 10 days after daily dosing.  Excretion of gefitinib and its metabolites is predominantly via the feces (86%), with renal elimination accounting for less than 4% of the administered dose.</p>
<p><span class="Italics">Specific Populations</span></p>
<p><span class="Italics">Age, gender, body weight, ethnicity or renal function</span>:  Population pharmacokinetic analyses suggest that patient age, body weight, ethnicity (populations included) or creatinine clearance (above 20 mL/min) has no clinically meaningful effect on predicted steady state trough concentration of gefitinib.  Population pharmacokinetic analyses of Study 1 showed that women had 27% higher exposure than men; however, this difference was not identified in the analyses of other gefitinib clinical studies.  No dose adjustment based on patient gender is recommended.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span>:  The systemic exposure of gefitinib was compared between patients with mild, moderate, or severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> due to cirrhosis (according to Child-Pugh classification) and healthy subjects with normal hepatic function (N=10/group).  The mean systemic exposure (AUC0-∞) was increased by 40% in patients with mild impairment, 263% in patients with moderate impairment, and 166% in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.  In a study comparing 13 patients with liver <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">metastases</span> and moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> to 14 patients with liver <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">metastases</span> and normal hepatic function, the systemic exposure of gefitinib was similar [<span class="Italics">see <a href="#ID_2d77f7d3-944b-4aea-9e6d-1a83f173b9b3">Warnings and Precautions (5.2)</a>, <a href="#ID_ce6adf8e-1aea-4074-8a22-c98b474f8495">Use in Specific Populations (8.7)</a></span>].</p>
<p><span class="Italics">CYP2D6 Poor metabolizer</span>:  CYP2D6 metabolizes gefitinib to O-desmethyl gefitinib <span class="Italics">in vitro</span>.  In healthy CYP2D6 poor metabolizers, O-desmethyl gefitinib concentration was not measurable and the mean exposure to gefitinib was 2-fold higher as compared to the extensive metabolizers.  This increase in exposure in CYP2D6 poor metabolizers may be clinically important because some adverse drug reactions are related to higher exposure of gefitinib.  No dose adjustment is recommended in patients with a known CYP2D6 poor metabolizer genotype, but these patients should be closely monitored for adverse reactions.  The impact of CYP2D6 inhibiting drugs on gefitinib pharmacokinetics has not been evaluated.  However, similar precautions should be used when administering CYP2D6 inhibitors with IRESSA because of the possibility of increased exposure in these patients.</p>
<p>An exploratory exposure response analysis showed an increase in the incidence of <span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">interstitial lung disease</span> (ILD) with a greater than 2 fold increase in the gefitinib exposure [<span class="Italics">see <a href="#ID_2d045521-95aa-4d4d-9692-ed8f004e43df">Warnings and Precautions (5.1)</a></span>].</p>
<p><span class="Italics">Drug-Drug Interactions</span></p>
<p><span class="Italics">Strong CYP3A4 Inducer:</span></p>
<p>Concomitant administration of rifampicin (600 mg QD for 16 days), a strong inducer of CYP3A4, with gefitinib (500 mg single dose on Day 10 of gefitinib administration) reduced mean AUC of gefitinib by 83% [<span class="Italics">see <a href="#ID_1131d2b6-1ce8-49f7-a380-78cf3ca3b3b5">Dosage and Administration (2.4)</a>, <a href="#ID_b227be78-1bf8-4067-a4cb-2b2a577754e9">Drug Interactions (7)</a></span>].</p>
<p><span class="Italics">CYP3A4 Inhibitor:</span></p>
<p>Concomitant administration of itraconazole (200 mg QD for 12 days), an inhibitor of CYP3A4, with gefitinib (250 mg single dose on Day 4 of itraconazole administration) to healthy male subjects, increased mean gefitinib AUC by 80% [<span class="Italics">see <a href="#ID_b227be78-1bf8-4067-a4cb-2b2a577754e9">Drug Interactions (7)</a></span>].</p>
<p><span class="Italics">Drugs Affecting Gastric pH:</span></p>
<p>Co-administration of high doses of ranitidine with sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> (to maintain the gastric pH above pH 5.0) to healthy subjects decreased mean gefitinib AUC by 47% [<span class="Italics">see <a href="#ID_b227be78-1bf8-4067-a4cb-2b2a577754e9">Drug Interactions (7)</a></span>].</p>
<p>In human liver microsome studies, gefitinib had no inhibitory effect on CYP1A2, CYP2C9, and CYP3A4 activities at concentrations ranging from 2-5000 ng/mL.  At the highest concentration studied (5000 ng/mL), gefitinib inhibited CYP2C19 by 24% and CYP2D6 by 43%.</p>
<p>Exposure to metoprolol, a substrate of CYP2D6, was increased by 30% when it was given on Day 15 of gefitinib dosing (500 mg daily for 28 days) in patients with <span class="product-label-link" type="condition" conceptid="4030314" conceptname="Neoplasm">solid tumors</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="ID_f86d37ec-4e82-40f0-8bde-6b170e59679c"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="ID_1b6766df-089a-4bee-8830-896d43ad8137"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Gefitinib has been tested for genotoxicity in a series of <span class="Italics">in vitro</span> (bacterial mutation, mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span>, and human lymphocyte) assays and an <span class="Italics">in vivo</span> rat micronucleus test.  Under the conditions of these assays, gefitinib did not cause genetic damage. </p>
<p>In a two-year carcinogenicity study in mice, administration of gefitinib at a dose of 270 mg/m<span class="Sup">2</span>/day (approximately twice the recommended daily dose of 250 mg on a mg/m<span class="Sup">2</span> basis; dose reduced from 375 mg/m<span class="Sup">2</span>/day from week 22) caused <span class="product-label-link" type="condition" conceptid="4301500" conceptname="Liver cell adenoma">hepatocellular adenomas</span> in females.  In a two-year carcinogenicity study in rats, administration of gefitinib at 60 mg/m<span class="Sup">2</span>/day (approximately 0.4 times the recommended daily clinical dose on a mg/m<span class="Sup">2</span> basis) caused <span class="product-label-link" type="condition" conceptid="4301500" conceptname="Liver cell adenoma">hepatocellular adenomas</span> and <span class="product-label-link" type="condition" conceptid="441818" conceptname="Hemangioma">hemangiomas</span>/hemagiosarcomas of the mesenteric lymph nodes in female rats.  The clinical relevance of these findings is unknown.</p>
<p>In a dedicated fertility study in rats at doses ≥120 mg/m<span class="Sup">2</span> (approximately equal to the recommended human dose of gefitinib on a mg/m<span class="Sup">2</span> basis), animals presented with an increased incidence of irregular estrous, decreased corpora lutea, and decreases in uterine implants and live embryos per litter. </p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="ID_fe83de02-e983-4558-94cb-37763a2c98b9"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First"><span class="Bold">Non-Small Cell Lung Cancer (NSCLC)</span></p>
<p><span class="Italics">Study 1</span></p>
<p>The efficacy and safety of IRESSA for the first-line treatment of patients with metastatic NSCLC containing EGFR exon 19 deletions or L858R substitution mutations was demonstrated in a multicenter, single-arm, open-label clinical study (Study 1).  A total of 106 treatment-naive patients with metastatic EGFR mutation positive NSCLC received IRESSA at a dose of 250 mg once daily until disease progression or intolerable toxicity.  The major efficacy outcome measure was objective response rate (ORR) according to RECIST v1.1 as evaluated by both a Blinded Independent Central Review (BICR) and investigators.  Duration of response (DOR) was an additional outcome measure.  Eligible patients were required to have a deletion in EGFR exon 19 or L858R, L861Q, or G719X substitution mutation and no T790M or S768I mutation or exon 20 insertion in tumor specimens as prospectively determined by a clinical trial assay.  Tumor samples from 87 patients were tested retrospectively using the <span class="Italics">therascreen</span><span class="Sup">®</span> EGFR RGQ PCR Kit.</p>
<p>The study population characteristics were:  median age 65 years, age 75 years or older (25%), age less than 65 years (49%), white (100%), female (71%), never smokers (64%), WHO PS 0 (45%), WHO PS 1 (48%), WHO PS 2 (7%), and adenocarcinoma histology (97%).  Sixty patients had exon 19 deletions (65%), 29 patients had L858R substitution (31%), while two patients each had tumors harboring L861Q or G719X substitution mutation.</p>
<p>The median duration of treatment was 8.0 months. Efficacy results from Study 1 are summarized below.</p>
<a name="_RefID0EZIAG"></a><table width="84.94%">
<caption><span>Table 3 – Efficacy Results in Study 1</span></caption>
<col width="45%">
<col width="24%">
<col width="30%">
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-8" href="#footnote-reference-8">*</a></dt>
<dd>BICR, Blinded Independent Central Review</dd>
<dt><a name="footnote-9" href="#footnote-reference-9">†</a></dt>
<dd>17 patients without target lesion at baseline detected by BICR were deemed non responders</dd>
<dt><a name="footnote-10" href="#footnote-reference-10">‡</a></dt>
<dd>Determined by RECIST v 1.1</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="Bold">Efficacy Parameter</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First"><span class="Bold">BICR</span><a name="footnote-reference-8" href="#footnote-8" class="Sup">*</a><span class="Bold"> Assessment</span></p>
<p><span class="Bold">(n=106)</span><a name="footnote-reference-9" href="#footnote-9" class="Sup">†</a></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Investigator Assessment</span><br><span class="Bold">(n=106)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">
<p class="First">Objective Response Rate<a name="footnote-reference-10" href="#footnote-10" class="Sup">‡</a></p>
<p>(95% CI)</p>
</td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First">50%</p>
<p>(41, 59)</p>
</td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First">70%</p>
<p>(61, 78)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Complete Response Rate</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.9%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1.9%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Partial Response Rate</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">49%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">68%</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule">
<p class="First">Median Duration of Response (months) </p>
<p>(95% CI)</p>
</td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First">6.0</p>
<p>(5.6, 11.1)</p>
</td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First">8.3</p>
<p>(7.6, 11.3)</p>
</td>
</tr>
</tbody>
</table>
<p>The response rates were similar in patients whose tumors had EGFR exon 19 deletions and exon 21 L858R substitution mutations.  Two partial responses were observed in both patients whose tumors had G719X substitution mutation with duration of response of at least 2.8 months and 5.6 months, respectively.  One of two patients whose tumors had L861Q substitution mutation also achieved a partial response with duration of response of at least 2.8 months.</p>
<p><span class="Italics">Study 2</span></p>
<p>The results of Study 1 were supported by an exploratory analysis of a subset of a randomized, multicenter, open-label trial (Study 2) conducted in patients with metastatic adenocarcinoma histology NSCLC receiving first-line treatment.  Patients were randomized (1:1) to receive IRESSA 250 mg orally once daily or up to 6 cycles of carboplatin/paclitaxel.  The efficacy outcomes included progression-free survival (PFS) and objective response rate (ORR) as assessed by BICR.</p>
<p>The subset population consisted of 186 of 1217 patients (15%)  determined to be EGFR positive by the same clinical trial assay as used in Study 1 and had radiographic scans available for a retrospective assessment by BICR.  In this subset, there were 88 IRESSA-treated patients and 98 carboplatin/paclitaxel-treated patients.</p>
<p>Demographic and baseline characteristics of this subset were a median age of 59 years, age 75 years or older (7%), age less than 65 (70%), Asian (100%), female (83%), never smokers (96%), adenocarcinoma histology (100%), and PS 0-1 (94%).  </p>
<p>The median duration of treatment for IRESSA-treated patients was 9.8 months.  The hazard ratio for PFS favored the IRESSA-treated patients [HR 0.54 (95% CI: 0.38, 0.79)] with a median PFS of 10.9 months for the IRESSA-treated patients and 7.4 months for the carboplatin/paclitaxel-treated patients as assessed by BICR.  In addition, the objective response rate was 67% (95% CI: 56, 77) for IRESSA-treated patients and 41% (95% CI: 31, 51) for carboplatin/paclitaxel-treated patients based on BICR assessment.  The median duration of response was 9.6 months for IRESSA-treated patients and 5.5 months for carboplatin/paclitaxel-treated patients. </p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="ID_8988ee29-ec80-49e7-9181-64207aa8b3c9"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">IRESSA<span class="Sup">® </span>(gefitinib) is available as 250 mg tablets.</p>
<p>IRESSA 250 mg tablets are round, biconvex, brown film-coated, debossed with "IRESSA 250" on one side and plain on the other side.</p>
<p>IRESSA<span class="Sup">® </span>(gefitinib) tablets are supplied as:</p>
<p>          Bottles of 30 Tablets (NDC 0310-0482-30) </p>
<p>Store at controlled room temperature 20°C-25°C (68°F-77°F) [see<span class="Italics"> USP Controlled Room Temperature</span>]. </p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="ID_ef5a2501-8d7e-4bba-80b4-f66227a6f905"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">Advise the patient to read the FDA-approved patient labelling (Patient Information).</p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">Interstitial Lung Disease</span></span>:  Advise patients to immediately contact their healthcare provider for new onset or worsening of pulmonary symptoms such as <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> [<span class="Italics">see <a href="#ID_2d045521-95aa-4d4d-9692-ed8f004e43df">Warnings and Precautions (5.1)</a></span>].</p>
<p><span class="Underline">Hepatotoxicity</span>:  Inform patients that they will need to undergo lab tests to monitor for liver function.  Advise patients to contact their healthcare provider to report any new symptoms indicating hepatic toxicity [<span class="Italics">see <a href="#ID_2d77f7d3-944b-4aea-9e6d-1a83f173b9b3">Warnings and Precautions (5.2)</a></span>].</p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="4202064" conceptname="Gastrointestinal perforation">Gastrointestinal Perforation</span></span>:  Advise patients that IRESSA can increase the risk of <span class="product-label-link" type="condition" conceptid="4202064" conceptname="Gastrointestinal perforation">gastrointestinal perforation</span> and to seek immediate medical attention for severe <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> [<span class="Italics">see <a href="#ID_a5ee96b2-ff22-43fc-85bc-138eb31489c5">Warnings and Precautions (5.3)</a></span>].</p>
<p><span class="Underline">Severe or Persistent <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></span>:  Advise patients to contact their healthcare provider for severe or persistent <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> [<span class="Italics">see <a href="#ID_c6e16281-54c6-47eb-bbce-fba14bf70e40">Warnings and Precautions (5.4)</a></span>].</p>
<p><span class="Underline">Ocular Disorders including <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">Keratitis</span></span>:  Advise patients promptly to contact their healthcare provider if they develop eye symptoms, <span class="product-label-link" type="condition" conceptid="435553" conceptname="Epiphora">lacrimation</span>, light sensitivity, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">eye pain</span>, <span class="product-label-link" type="condition" conceptid="442546" conceptname="Red eye">red eye</span> or changes in vision [<span class="Italics">see <a href="#ID_b08651dd-f6b1-4fdd-993c-c251d00ce1ff">Warnings and Precautions (5.5)</a></span>].</p>
<p><span class="Underline">Bullous and Exfoliative <span class="product-label-link" type="condition" conceptid="140842" conceptname="Changes in skin texture">Skin Disorders</span></span>:  Advise patients that IRESSA can increase the risk of bullous and exfoliative <span class="product-label-link" type="condition" conceptid="140842" conceptname="Changes in skin texture">skin disorders</span> and to seek immediately medical attention for severe <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> [<span class="Italics">see <a href="#ID_580caeb9-b38c-48a0-a048-92af625dad0b">Warnings and Precautions (5.6)</a></span>].</p>
<p><span class="Underline">Embryo-fetal Toxicity</span>:  Advise pregnant women of the potential risk to a fetus or potential risk for loss of the pregnancy [<span class="Italics">see <a href="#ID_a349679d-8114-4808-876f-1e8a87878c53">Warnings and Precautions (5.7)</a>, <a href="#ID_aed3107a-7c80-44f6-8f59-b839375bfd3e">Use in Specific Populations (8.1)</a></span>].  Advise females of reproductive potential to use effective contraception during treatment with IRESSA and for at least two weeks following completion of therapy [<span class="Italics">see <a href="#ID_32a77107-3925-4c54-a304-f0265cf650ff">Use in Specific Populations (8.3)</a></span>].</p>
<p><span class="Underline">Lactation</span>:  Advise women to discontinue breast-feeding during treatment with IRESSA [<span class="Italics">see <a href="#ID_8168cd39-6a10-42ba-b5ad-57d43110c759">Use in Specific Populations (8.2)</a></span>].</p>
<p>IRESSA is a trademark of the AstraZeneca group of companies.</p>
<p>©AstraZeneca 2015</p>
<p>Manufactured for:</p>
<p>AstraZeneca Pharmaceuticals LP</p>
<p>Wilmington, DE 19850</p>
<p>By: AstraZeneca UK Limited</p>
<p>Macclesfield, Cheshire, England</p>
<p>Product of Belgium</p>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="ID_1a756aa0-c353-470e-a91b-194075360ef8"></a><a name="section-16"></a><p></p>
<p class="First"><span class="Bold">Patient Information</span></p>
<p><span class="Bold">IRESSA </span>(eye-RES-sah)</p>
<p><span class="Bold">(gefitinib) tablets</span></p>
<p><span class="Bold">What is IRESSA?</span></p>
<p>IRESSA is a prescription medicine used to treat people with non-small cell lung cancer (NSCLC) that has spread to other parts of the body and:</p>
<dl>
<dt>•</dt>
<dd>that have certain types of abnormal epidermal growth factor receptor (EGFR) genes, and </dd>
<dt>•</dt>
<dd>who have not had previous treatment for cancer</dd>
</dl>
<p>Your healthcare provider will perform a test to make sure that IRESSA is right for you.</p>
<p>It is not known if IRESSA is safe and effective in people with NSCLC that have other types of EGFR genes.</p>
<p>It is not known if IRESSA is safe and effective in children.</p>
<p><span class="Bold">Before taking IRESSA, tell your healthcare provider about all of your medical conditions, including if you:</span></p>
<dl>
<dt>•</dt>
<dd>have lung or breathing problems</dd>
<dt>•</dt>
<dd>ever had liver problems</dd>
<dt>•</dt>
<dd>have vision or eye problems</dd>
<dt>•</dt>
<dd>are pregnant or plan to become pregnant. IRESSA can harm your unborn baby.<dl>
<dt>•</dt>
<dd>Females who are able to become pregnant should use an effective method of birth control during treatment with IRESSA and for at least 2 weeks after the last dose of IRESSA. You should avoid becoming pregnant during treatment with IRESSA.</dd>
<dt>•</dt>
<dd>Tell your healthcare provider right away if you become pregnant during treatment with IRESSA.</dd>
</dl>
</dd>
<dt>•</dt>
<dd>are breastfeeding or plan to breastfeed. It is not known if IRESSA passes into your breast milk. Do not breastfeed during treatment with IRESSA. Talk to your healthcare provider about the best way to feed your baby during this time.</dd>
</dl>
<p>Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, or herbal supplements.</p>
<p>If you take a proton pump inhibitor (PPI), H2 blocker, or an antacid medicine, talk to your healthcare provider about the best time to take it during treatment with IRESSA.</p>
<p>If you take a blood thinner called warfarin, your healthcare provider should do blood tests regularly to check how fast your blood clots, during treatment with IRESSA.</p>
<p><span class="Bold">How should I take IRESSA?</span></p>
<dl>
<dt>•</dt>
<dd>Take IRESSA exactly as your healthcare provider tells you to take it.</dd>
<dt>•</dt>
<dd>Your healthcare provider may change your dose, temporarily stop, or permanently stop treatment with IRESSA if you have side effects.</dd>
<dt>•</dt>
<dd>Take IRESSA 1 time each day.</dd>
<dt>•</dt>
<dd>You can take IRESSA with or without food.</dd>
<dt>•</dt>
<dd>If you miss a dose of IRESSA, take it as soon as you remember. If it is less than 12 hours until your next dose, skip the missed dose. Take your next dose at your regular time.</dd>
<dt>•</dt>
<dd>If you take too much IRESSA, call your healthcare provider or go to the nearest emergency room right away.</dd>
<dt>•</dt>
<dd>
<span class="Bold">If you cannot swallow IRESSA tablets whole:</span><dl>
<dt>•</dt>
<dd>place your dose of IRESSA in a container with 4 to 8 ounces of water and stir for about 15 minutes</dd>
<dt>•</dt>
<dd>drink the mixture right away</dd>
<dt>•</dt>
<dd>place another 4 to 8 ounces of water in the same container, and drink it right away</dd>
</dl>
</dd>
</dl>
<p><span class="Bold">What are the possible side effects of IRESSA?</span></p>
<p><span class="Bold">IRESSA may cause serious side effects, including:</span></p>
<dl>
<dt>•</dt>
<dd>
<span class="Bold">lung or breathing problems</span>.  IRESSA may cause <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> of the lung that may lead to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Symptoms may be similar to those symptoms from lung cancer. Tell your healthcare provider right away if you have any new or worsening lung problems, or any combination of the following symptoms: trouble breathing or <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, or <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>.</dd>
<dt>•</dt>
<dd>
<span class="Bold">liver problems</span>. IRESSA may cause <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> of the liver that may lead to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Tell your healthcare provider right away if you have any symptoms of a liver problem which may include:<dl>
<dt>•</dt>
<dd>yellowing of your skin or the white part of your eyes (<span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>)</dd>
<dt>•</dt>
<dd>dark or brown (tea colored) urine</dd>
<dt>•</dt>
<dd>light-colored bowel movements (stools)</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">decreased appetite</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> on the right side of your stomach (abdomen)</dd>
</dl>
</dd>
</dl>
<p>Your healthcare provider will do blood tests to check your liver function during your treatment with IRESSA.</p>
<dl>
<dt>•</dt>
<dd>
<span class="Bold">a tear in the wall of your stomach or intestines (perforation)</span>. Get emergency medical help right away if you have severe stomach (abdomen) <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>.</dd>
<dt>•</dt>
<dd>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></span>. <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> is common with IRESSA and can sometimes be severe. Tell your healthcare provider right away if you have severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> that will not go away.</dd>
<dt>•</dt>
<dd>
<span class="Bold">eye problems</span>. Tell your healthcare provider if you get watery eyes, sensitivity to light, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">eye pain</span>, <span class="product-label-link" type="condition" conceptid="442546" conceptname="Red eye">eye redness</span>, or vision changes.</dd>
<dt>•</dt>
<dd>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span></span>. Skin <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, and <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> are common with IRESSA. This may occur on any part of your body. Get medical help right away if you develop severe <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> such as <span class="product-label-link" type="condition" conceptid="4032013" conceptname="Desquamation">peeling</span> or <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blistering</span> of your skin.</dd>
</dl>
<p>IRESSA may cause fertility problems in females. Talk to your healthcare provider if you plan to become pregnant.</p>
<p>Tell your healthcare provider if you have any side effect that bothers you or that does not go away.</p>
<p>These are not all the possible side effects of IRESSA. For more information, ask your healthcare provider or pharmacist.</p>
<p>Call your doctor for medical advice about side effects.</p>
<p>You may report side effects to FDA at 1-800-FDA-1088.</p>
<p><span class="Bold">How should I store IRESSA? </span></p>
<p>Store IRESSA at room temperature between 68˚F to 77˚F (20˚C to 25˚C)</p>
<p><span class="Bold">Keep IRESSA and all medicines out of the reach of children.</span></p>
<p><span class="Bold">General information about the safe and effective use of IRESSA.</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in Patient Information leaflet. Do not use IRESSA for a condition for which it was not prescribed. Do not give IRESSA to other people, even if they have the same symptoms you have. It may harm them. You can ask your healthcare provider or pharmacist for information about IRESSA that is written for health professionals. </p>
<p><span class="Bold">What are the ingredients in IRESSA?</span></p>
<p><span class="Bold">Active ingredient</span>:  gefitinib</p>
<p><span class="Bold">Inactive ingredients</span>:  lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, povidone, sodium lauryl sulfate, magnesium stearate</p>
<p><span class="Bold">Tablet coating contains</span>:  hypromellose, polyethylene glycol 300, titanium dioxide, yellow iron oxide and red iron oxide.</p>
<p>IRESSA is a trademark of the AstraZeneca group of companies.</p>
<p>©AstraZeneca 2015</p>
<p>Manufactured for: AstraZeneca Pharmaceuticals LP Wilmington, DE 19850</p>
<p>Manufactured by: AstraZeneca UK Limited Macclesfield, Cheshire, England </p>
<p>Product of Belgium</p>
<p>For more information, go to www.iressa.com or call 1-800-236-9933</p>
<p>This Patient Information has been approved by the U.S. Food and Drug Administration.	Issued: July 2015</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_6fa14ad8-0ed2-47b9-9ae0-198cf614caeb"></a><a name="section-17"></a><p></p>
<h1>PACKAGE/LABEL PRINCIPAL DISPLAY PANEL – 250 mg</h1>
<p class="First">NDC 0310-0482-30</p>
<p>30 tablets</p>
<p>IRESSA®</p>
<p>(gefitinib) tablets</p>
<p>250 mg</p>
<p>Manufactured for: </p>
<p>AstraZeneca Pharmaceuticals LP</p>
<p>Wilmington, DE 19850</p>
<p>By:  AstraZeneca UK Limited</p>
<p>Macclesfield, Cheshire, England</p>
<p>Product of Belgium</p>
<p>AstraZeneca</p>
<div class="Figure">
<a name="id-1734175685"></a><img alt="Iressa 250mg - 30 tablet count bottle label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=827d60e8-7e07-41b7-c28b-49ef1c4a5a41&amp;name=image-02.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>IRESSA 		
					</strong><br><span class="contentTableReg">gefitinib tablet, coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0310-0482</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>GEFITINIB</strong> (GEFITINIB) </td>
<td class="formItem">GEFITINIB</td>
<td class="formItem">250 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POVIDONES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM LAURYL SULFATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 300</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BROWN</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (biconvex) </td>
<td class="formLabel">Size</td>
<td class="formItem">11mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">IRESSA;250</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0310-0482-30</td>
<td class="formItem">30  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA206995</td>
<td class="formItem">07/13/2015</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>AstraZeneca Pharmaceuticals LP
							(054743190)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>AstraZeneca PLC (230790719)</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 7/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>3f370299-c18c-4fe0-bbfc-3ada9f57115e</div>
<div>Set id: 827d60e8-7e07-41b7-c28b-49ef1c4a5a41</div>
<div>Version: 8</div>
<div>Effective Time: 20150713</div>
</div>
</div> <div class="DistributorName">AstraZeneca Pharmaceuticals LP</div></p>
</body></html>
